User contributions for Alen Antony
Results for Alen Antony talk block log uploads logs
A user with 103 edits. Account created on 7 February 2024.
3 May 2024
- 18:5718:57, 3 May 2024 diff hist +210 Perfluorhexyloctane No edit summary
- 18:2018:20, 3 May 2024 diff hist +251 N Perfluorhexyloctane Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=perfluorhexyloctane |aOrAn=a |drugClass=semifluorinated alkane |indicationType=treatment |indication=signs and symptoms of dry eye disease (DED). |adverseReactions=blurred vision. }}"
2 May 2024
- 15:2915:29, 2 May 2024 diff hist +74 N Trofinetide Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=trofinetide }}"
- 04:0404:04, 2 May 2024 diff hist +2,901 Zavegepant No edit summary current
- 03:2903:29, 2 May 2024 diff hist +1,496 N Zavegepant Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zavegepant |aOrAn=a |drugClass=calcitonin gene-related peptide (CGRP) receptor antagonist. |indicationType=treatment |indication=acute migraine with or without aura in adults. |adverseReactions=taste disorders, nausea, nasal discomfort, and vomiting |fdaLIADAdult=The recommended dose is 10 mg given intranasally as a single spray in one nostril, as needed, with the maximum dosage at 10mg in 24 hours. |contraindic..."
- 02:1302:13, 2 May 2024 diff hist +439 Omaveloxolone No edit summary current
- 02:1002:10, 2 May 2024 diff hist +619 Omaveloxolone No edit summary
- 02:0502:05, 2 May 2024 diff hist +435 Omaveloxolone No edit summary
- 01:1401:14, 2 May 2024 diff hist +1,542 Omaveloxolone No edit summary
1 May 2024
- 23:4923:49, 1 May 2024 diff hist +272 Omaveloxolone No edit summary
- 23:1223:12, 1 May 2024 diff hist +836 Omaveloxolone No edit summary
- 23:0223:02, 1 May 2024 diff hist +1,322 Omaveloxolone No edit summary
- 22:2022:20, 1 May 2024 diff hist +287 Omaveloxolone No edit summary
- 21:5121:51, 1 May 2024 diff hist +76 N Omaveloxolone Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=omaveloxolone }}"
26 April 2024
- 04:2704:27, 26 April 2024 diff hist +1,079 Daprodustat No edit summary current
25 April 2024
- 21:2121:21, 25 April 2024 diff hist +952 Daprodustat No edit summary
- 20:5320:53, 25 April 2024 diff hist +1,266 Daprodustat No edit summary
- 19:0719:07, 25 April 2024 diff hist +2,809 Daprodustat No edit summary
- 17:2317:23, 25 April 2024 diff hist +563 Daprodustat No edit summary
- 16:4716:47, 25 April 2024 diff hist +147 Daprodustat No edit summary
- 15:2315:23, 25 April 2024 diff hist +1,157 N Daprodustat Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=daprodustat |aOrAn=a |drugClass=reversible inhibitor of HIF-PH1, PH2 and PH3. |indicationType=treatment |indication=anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. |hasBlackBoxWarning=Yes |adverseReactions=Hypertension, Abdominal pain, Dizzines, Hypersensitivity, and thrombotic vascular events like Myocardial infarction, stroke, pulmonary embolism,..."
- 01:5001:50, 25 April 2024 diff hist +1,145 Bexagliflozin No edit summary current
- 00:5700:57, 25 April 2024 diff hist +669 Bexagliflozin No edit summary
- 00:5000:50, 25 April 2024 diff hist +1,349 Bexagliflozin No edit summary
- 00:1700:17, 25 April 2024 diff hist +786 Bexagliflozin No edit summary
24 April 2024
- 23:3523:35, 24 April 2024 diff hist +245 Bexagliflozin No edit summary
- 23:1123:11, 24 April 2024 diff hist +1,453 Bexagliflozin No edit summary
- 22:5522:55, 24 April 2024 diff hist +164 Bexagliflozin No edit summary
- 21:0621:06, 24 April 2024 diff hist +76 N Bexagliflozin Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=bexagliflozin }}"
29 February 2024
- 04:5204:52, 29 February 2024 diff hist +1,033 Lecanemab-irmb No edit summary current
- 04:3004:30, 29 February 2024 diff hist +4 Lecanemab-irmb No edit summary
- 02:1602:16, 29 February 2024 diff hist +607 N Lecanemab-irmb Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=lecanemab-irmb |aOrAn=a |drugClass=recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody |indicationType=treatment |indication=Alzheimer’s disease. This drug is ideally initiated during the early phase of dementia or mild cognitive impairment (which was the population tested in the clinical trials of this drug). |hasBlackBoxWarning=Yes |adverseReactions=Amyloid Related Imaging Abnorma..."
21 February 2024
- 06:2106:21, 21 February 2024 diff hist +2,917 N Olutasidenib Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Olutasidenib |aOrAn=a |drugClass=isocitrate dehydrogenase-1 (IDH1) inhibitor |indicationType=treatment |indication=relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. |hasBlackBoxWarning=Yes |adverseReactions=nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, mucositis, arthralgia, fatigue, pyrexia..." current
- 00:2100:21, 21 February 2024 diff hist +4 Lenacapavir No edit summary current
- 00:0400:04, 21 February 2024 diff hist +4,906 Lenacapavir No edit summary
20 February 2024
- 23:1123:11, 20 February 2024 diff hist +2,687 Lenacapavir No edit summary
15 February 2024
- 16:2916:29, 15 February 2024 diff hist +549 Lenacapavir No edit summary
- 06:3006:30, 15 February 2024 diff hist +74 N Lenacapavir Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=lenacapavir }}"
- 06:0906:09, 15 February 2024 diff hist +1,439 Tirzepatide No edit summary current
- 02:3202:32, 15 February 2024 diff hist +1,564 Tirzepatide No edit summary
- 00:3600:36, 15 February 2024 diff hist +8,168 Tirzepatide No edit summary
14 February 2024
- 21:2521:25, 14 February 2024 diff hist +571 N Tirzepatide Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=tirzepatide |aOrAn=a |drugClass=glucagon-like peptide-1 (GLP-1) receptor agonist |indicationType=treatment |indication=type 2 diabetes mellitus in adults in adjunct to diet and exercise. |hasBlackBoxWarning=Yes |adverseReactions=pancreatitis,hypoglycemia with concomitant use of insulin or insulin secretagogues, acute kidney injury, severe gastrointestinal disease, acute gallbladder disease, dia..."
- 20:0420:04, 14 February 2024 diff hist +1,993 Spesolimab-sbzo No edit summary current
- 19:1819:18, 14 February 2024 diff hist +2,223 Spesolimab-sbzo No edit summary
- 07:1207:12, 14 February 2024 diff hist +17 Spesolimab-sbzo No edit summary
- 07:0507:05, 14 February 2024 diff hist +3,687 N Spesolimab-sbzo Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Spesolimab-sbzo |drugClass=humanized monoclonal Immunoglobulin G1 antibody |indicationType=treatment |indication=generalized pustular psoriasis (GPP) flares in adults. |adverseReactions=infections, nausea, vomiting, headache, fatigue, Infusion site hematoma and bruising. |fdaLIADAdult=SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults. SPEVIGO is administer..."
13 February 2024
- 22:2722:27, 13 February 2024 diff hist +1,322 Mosunetuzumab-axgb No edit summary current
- 07:1007:10, 13 February 2024 diff hist +7,218 Mosunetuzumab-axgb No edit summary
12 February 2024
- 22:3022:30, 12 February 2024 diff hist +2,053 N Mosunetuzumab-axgb Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=mosunetuzumab-axgb |aOrAn=a |drugClass=humanized monoclonal antibody |indicationType=treatment |indication=relapsing or refractory follicular lymphoma in adults after 2 or more lines of systemic therapy. |hasBlackBoxWarning=Yes |adverseReactions=cytokine release syndrome, fatigue, rash, pyrexia, and headache. |blackBoxWarningTitle=Cytokine Release Syndrome (CRS) |blackBoxWarningBody=Cytok..."
11 February 2024
- 06:1306:13, 11 February 2024 diff hist +84 N Template:AAP Created page with "Alen Antony Pathil, M.D.[mailto:alenantony657@gmail.com]" current